Tempus Launches AI Prostate Test for Advanced Cancer
Chicago, Illinois, USA – May 21, 2026 Tempus AI, Inc., a leader in artificial intelligence and precision medicine, announced...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Chicago, Illinois, USA – May 21, 2026 Tempus AI, Inc., a leader in artificial intelligence and precision medicine, announced...
WHIPPANY, N.J., May 21, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
SAN CLEMENTE, Calif., May 20, 2026 Reflow Medical, Inc. has announced encouraging six-month clinical results from its DEEPER CORONARY...
MENLO PARK, Calif., May 20, 2026 Jupiter Endovascular announced positive topline results from the pivotal SPIRARE II clinical trial...
ZUG, Switzerland, May 20, 2026 Implantica AG announced that it has submitted its final response to the U.S. Food...
AMSTERDAM, Netherlands, May 18, 2026 Royal Philips has introduced SmartIQ, a breakthrough AI-enabled coronary imaging technology developed for its...
